Arcus Biosciences RCUS anti-CD39 — Milestone payments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept rcus:MilestonePayments.
The official record: Arcus Biosciences’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's anti-cd39 — milestone payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's anti-cd39 — milestone payments?
- Arcus Biosciences (RCUS) reported anti-cd39 — milestone payments of $0 in Q4 2025.
- What is the long-term trend for Arcus Biosciences's anti-cd39 — milestone payments?
- Over 3 years (2022 to 2025), Arcus Biosciences's anti-cd39 — milestone payments has grown at a -100.0% compound annual growth rate (CAGR), from $2M to $0.
- What does anti-cd39 — milestone payments mean?
- This metric tracks the total cash outflows associated with achieving predefined performance or development milestones for anti-CD39 assets. These payments are typically stipulated in licensing or collaboration agreements to incentivize progress in the drug development lifecycle. It provides insight into the ongoing cost structure of maintaining external partnerships for specific therapeutic assets.